Drugs / High Dose Quadrivalent Influenza Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05426174 Comparator | Jun 2022 → Jan 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High Dose Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05426174 ↗ |
| Modality | Vaccine | “High Dose Quadrivalent Influenza Vaccine” NCT05426174 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT05426174 ↗ |